Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion type Assertion NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_head.
- NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion wasGeneratedBy ECO_0000203 NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_provenance.
- NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion wasDerivedFrom befree-20140225 NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_provenance.
- NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion SIO_000772 22271575 NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_provenance.
- NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion evidence source_evidence_literature NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_provenance.
- NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_assertion description "[Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650205.RAY4gOTlKHzgN0hYQ-m4YOmQ9ogyDQUCBGuM8tm4eDP8I130_provenance.